EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY-NC-ND 4.0

Interpreting long‐term response to rituximab in immune thrombocytopenia: Cohort construction, treatment attribution, and dynamic prognostication

Xin Zhou iD, Ningning Shan iD

HemaSphere · 2026-10 · 10 (10)

DOI: 10.1002/hem3.70519 ↗

Kurz gefasst

Editorial in der Zeitschrift HemaSphere, online erschienen am 27.10.2026. Verfasst von Xin Zhou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology The Second Qilu Hospital of Shandong University Jinan Shandong China. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Hematology The Second Qilu Hospital of Shandong University Jinan Shandong China.
  • Department of Hematology, The Second Hospital of Shandong University Shandong Key Laboratory of Cancer Digital Medicine Jinan Shandong China.
  • Institute of Biotherapy for Hematological Malignancies, Shandong University Jinan China.

ORCID-Profile: Xin Zhou, Ningning Shan

Zitieren

APA

Zhou, X., & Shan, N. (2026). Interpreting long‐term response to rituximab in immune thrombocytopenia: Cohort construction, treatment attribution, and dynamic prognostication. HemaSphere, 10(10). https://doi.org/10.1002/hem3.70519

Vancouver

Zhou X, Shan N. Interpreting long‐term response to rituximab in immune thrombocytopenia: Cohort construction, treatment attribution, and dynamic prognostication. HemaSphere. 2026;10(10). doi:10.1002/hem3.70519

BibTeX
@article{Zhou2026,
  author = {Zhou, Xin and Shan, Ningning},
  title = {Interpreting long‐term response to rituximab in immune thrombocytopenia: Cohort construction, treatment attribution, and dynamic prognostication},
  journal = {HemaSphere},
  year = {2026},
  volume = {10},
  number = {10},
  doi = {10.1002/hem3.70519}
}
Kostenlos starten →